3 recruiting. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 3 |
| Phase 1 | 1 | Recruiting 1 |
Follow Lu-PSMA-617: new trials by email Literature Review of Lu-PSMA-617 trials Research Report on Lu-PSMA-617
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 68Ga-PSMA-11 PET-directed Radioligand Therapy in Metastatic Hepatocellular Carcinoma (HCC) Lu-PSMA-617 - Liver Cancer, Hepatocellular Carcinoma | Phase 2 | Recruiting | Melissa Lumish | 10 | 2026-06-01 | 2026-05-08 |
| Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer Cabazitaxel and carboplatin, Lu-PSMA-617 - Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer | Phase 2 | Recruiting | Case Comprehensive Cancer Center | 44 | 2025-07-14 | 2026-10-02 |
| STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer Lu-PSMA-617, 5-fraction Stereotactic Body Radiation Therapy (SBRT) - Malignant Neoplasm of Prostate, Locally Advanced Prostate Cancer | Phase 1 / Phase 2 | Recruiting | Angela Y. Jia, MD PhD | 45 | 2025-05-13 | 2026-05-26 |
Prostatic Neoplasms (2) · Carcinoma, Hepatocellular (1) · Liver Neoplasms (1)
Angela Y. Jia, MD PhD (1) · Case Comprehensive Cancer Center (1) · Melissa Lumish (1)
United States (3)
Angela Y Jia, MD, PhD (1) · Daniel E Spratt, MD (1) · Melissa Lumish, MD (1) · Pedro Barata, MD, MSc (1)